{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T13:41:04Z","timestamp":1761572464041,"version":"build-2065373602"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["1R01DA056446"],"award-info":[{"award-number":["1R01DA056446"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context\/background<\/jats:title>\n                    <jats:p>The high prevalence of opioid use among jailed adults offers an unmatched opportunity to identify and treat those with opioid use disorder (OUD), a population that is at a substantial risk for post-release overdose. From a public health perspective, jails are critical touchpoints, as these facilities typically admit more than 7\u00a0million adults per year. One clinical consideration is whether pre-trial detainees with OUD would benefit from early induction onto extended-release buprenorphine (XRB).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods\/study design<\/jats:title>\n                    <jats:p>\n                      In this 3-year randomized controlled trial, we will identify and recruit 200 incarcerated adults with OUD who are receiving sublingual buprenorphine (SLB) or tolerate a SLB test dose and randomize them to receive extended release buprenorphine (XRB) (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009100) or to remain on SLB (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009100) while in custody. Study participation will continue through their pre-trial time in jail (up to 6 months) or until they are sentenced or released. Community treatment will then be tracked for 90 days following release. In addition to collecting data on XRB uptake in jail, we will assess (1) the percentage of XRB and SLB study participants leaving jail with a clinically active dose of buprenorphine in their system, (2) 90- day post-release MOUD continuation, (3) levels of buprenorphine diversion while in custody, and (4) recidivism and death (90 days). \u201cClinically active\u201d is defined as receiving XRB within the past 28 days or SLB in the past 24\u00a0h.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Findings from this study will demonstrate the feasibility and outcomes of inducting pre-trial adults with OUD onto XRB, as well as offer practical clinical and policy guidelines for best practices for treating this high risk and understudied population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13722-025-00611-9","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T12:32:44Z","timestamp":1761568364000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A protocol for a randomized comparison of extended-release versus sublingual buprenorphine among pre-trial detainees in jail"],"prefix":"10.1186","volume":"20","author":[{"given":"Rebecca E.","family":"Rottapel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Stopka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter D.","family":"Friedmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randall A.","family":"Hoskinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daviana","family":"Englander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Calhoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Senst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Gudas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"Koutoujian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0398-205X","authenticated-orcid":false,"given":"David","family":"Farabee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"611_CR1","unstructured":"Zeng Z. Jail Inmates in 2022 \u2013 Statistical Tables [Internet]. U.S. Dept. of Justice: Bureau of Justice Statistics; 2023 Dec p. 30. (Jail Inmates, Prison and Jail Inmates at Midyear). Report No.: 36. Available from: https:\/\/bjs.ojp.gov\/library\/publications\/jail-inmates-2022-statistical-tables"},{"key":"611_CR2","unstructured":"Baker CD, Polito KE, Sudders M, Bharel M. An Assessment of Fatal and Nonfatal Opioid Overdoses in Massachusetts (2011\u20132015) [Internet]. The Commonwealth of Massachusetts Executive Office of Health and Human Services Department of Public Health; 2017 Aug [cited 2022 Jan 15] p. 105. Available from: https:\/\/www.mass.gov\/files\/documents\/2017\/08\/31\/legislative-report-chapter-55-aug-2017.pdf?_gl=1*urhte2*_ga*MTgzMDc4OTM5MS4xNjc0NzYyOTg2*_ga_MCLPEGW7WM*MTcyMDYzMjc3OC4yLjAuMTcyMDYzMjc3OC4wLjAuMA.&_ga=2.105902469.741819254.1720629533-1830789391.1674762986"},{"key":"611_CR3","doi-asserted-by":"crossref","unstructured":"Scott CK, Grella CE, Dennis ML, Carnevale J, LaVallee R. Availability of best practices for opioid use disorder in jails and related training and resource needs: findings from a national interview study of jails in heavily impacted counties in the U.S. Health & Justice. 2022;10(1):36.","DOI":"10.1186\/s40352-022-00197-3"},{"issue":"4","key":"611_CR4","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1097\/ADM.0000000000000942","volume":"16","author":"J Berk","year":"2022","unstructured":"Berk J, Del Pozo B, Rich JD, Lee JD. Injecting opioid use disorder treatment in jails and prisons: the potential of extended-release buprenorphine in the carceral setting. J Addict Med. 2022;16(4):396\u20138.","journal-title":"J Addict Med"},{"key":"611_CR5","unstructured":"Goldstein R, Healey M, Driscoll K. Walsh K. Outcomes of the medications for opioid use disorder (MOUD) in correctional facilities pilot program [Internet]. Executive Office of Health and Human Services Department of Public Health: The Commonwealth of Massachusetts; 2024 June p. 18. Available from: https:\/\/www.mass.gov\/doc\/chapter-208-2024-legislative-report\/download"},{"key":"611_CR6","doi-asserted-by":"crossref","unstructured":"Stopka T, Rottapel R, Ferguson W, Pivovarova E, Del Toro-Mejias L, Friedmann P, et al. Medication for opioid use disorder treatment continuity post-release from jail: a qualitative study with community-based treatment providers. Internat J Drug Policy [Internet]. 2022;110. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0955395922002195?via%3Dihub","DOI":"10.1016\/j.drugpo.2022.103803"},{"key":"611_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.drugpo.2022.103823","volume":"109","author":"A Matsumoto","year":"2022","unstructured":"Matsumoto A, Santelices C, Evans EA, Pivovarova E, Stopka TJ, Ferguson WJ, et al. Jail-based reentry programming to support continued treatment with medications for opioid use disorder: qualitative perspectives and experiences among jail staff in Massachusetts. Int J Drug Policy. 2022;109:7.","journal-title":"Int J Drug Policy"},{"key":"611_CR8","doi-asserted-by":"crossref","unstructured":"Lee JD, Malone M, McDonald R, Cheng A, Vasudevan K, Tofighi B, et al. Comparison of treatment retention of adults with opioid addiction managed with extended-release buprenorphine vs daily sublingual buprenorphine-naloxone at time of release from jail. JAMA Netw Open. 2021 Sept 1;4(9):e2123032.","DOI":"10.1001\/jamanetworkopen.2021.23032"},{"key":"611_CR9","unstructured":"Statistical Atlas [Internet]. The Demographic Statistical Atlas of the United States. [cited 2024 July 19]. Available from: https:\/\/statisticalatlas.com\/division\/New-England\/Population#data-map\/county"},{"issue":"1","key":"611_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1080\/08897077.2014.932320","volume":"36","author":"IA Binswanger","year":"2015","unstructured":"Binswanger IA, Whitley E, Haffey PR, Mueller SR, Min SJ. A patient navigation intervention for drug involved former prison inmates. Subst Abus. 2015;36(1):34\u201341.","journal-title":"Subst Abus"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00611-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-025-00611-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00611-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T12:32:46Z","timestamp":1761568366000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-025-00611-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["611"],"URL":"https:\/\/doi.org\/10.1186\/s13722-025-00611-9","relation":{},"ISSN":["1940-0640"],"issn-type":[{"type":"electronic","value":"1940-0640"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"4 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"David Farabee has received study medication from Indivior and Alkermes. Peter D. Friedmann has served as a member of the scientific advisory board for Indivior.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"88"}}